Dec 20, 2020 | Press Releases
ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort...Dec 20, 2020 | Press Releases
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious...Dec 10, 2020 | Press Releases
BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The...Nov 23, 2020 | Press Releases
N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and Functionality Adding N-803 to NK Cell Therapy has Potential to Improve Cancer Immunotherapy CULVER CITY Calif., November 23, 2020 — ImmunityBio, a privately-held immunotherapy company, today announced the...Nov 18, 2020 | Press Releases
EL SEGUNDO, Calif., November 18, 2020 – NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32nd Annual Piper Sandler Healthcare conference, which takes place December 1-3,...Nov 10, 2020 | Press Releases
First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAEs), high dose cohort safety analysis ongoingSubject screening is ongoing for Phase I expansion cohortsPhase 2 / 3 hAd5 COVID-19 trial in designCULVER CITY & EL SEGUNDO,...